Collaboration Announcement: Somite Therapeutics and OmniaBio
This partnership aims to advance cell replacement therapy for a serious genetic disorder.
Somite Therapeutics and OmniaBio Inc. have joined forces to enhance the production of cell therapies specifically for Duchenne muscular dystrophy (DMD). Their collaboration is focused on refining the development of SMT-M01, an innovative therapy that has the potential to restore muscle function in individuals affected by this challenging condition.
Professor Peter Zandstra expressed great enthusiasm for this partnership, highlighting its potential to drive long-term advancements not only for this specific program but also for the broader field of cell therapy. He underscored Somite’s pioneering use of artificial intelligence in discovering and optimizing cell therapies, which opens up exciting opportunities to improve both the effectiveness and cost-efficiency of these treatments.
Duchenne muscular dystrophy is a serious genetic disorder that leads to progressive muscle degeneration and currently has no cure. This collaboration aims to combine the expertise of both companies to create an advanced cell replacement therapy that can slow the disease's progression and significantly enhance the quality of life for those diagnosed with DMD.
Dr. Kristy Brown from Somite Therapeutics noted that collaborating with OmniaBio provides invaluable experience in iPSC technology, which is crucial for the efficient advancement of their DMD program. This partnership instills confidence in the development process and ensures regulatory compliance, allowing for the expedited delivery of vital therapies to patients in need.
As part of the collaboration, OmniaBio will oversee several essential processes, including master cell banking, pluripotent stem cell differentiation, and the optimization of harvesting conditions for drug production. This methodical approach is grounded in their extensive experience with induced pluripotent stem cell technology.
Looking forward, Dr. Micha Breakstone, CEO of Somite Therapeutics, mentioned that they expect to enter phase one/two clinical trials within the next eighteen to twenty-four months. He shared his excitement about how this collaboration could transform patient outcomes and further advance the field of stem cell biology.
Mitchel Sivilotti, President and CEO of OmniaBio, also expressed optimism about how their combined efforts could lead to groundbreaking innovations in treatments for DMD patients around the world. He pointed out that their deep knowledge of iPSC technology, along with a growing emphasis on AI-driven innovations, will be crucial in enhancing manufacturing processes and speeding up clinical translation.
About Somite Therapeutics
Recently established, Somite Therapeutics is committed to revolutionizing stem cell biology by integrating artificial intelligence with cell therapy research. Their unique AI-powered platform, known as AlphaStem, aims to create human tissues for cell therapies targeting various diseases, including diabetes, obesity, and muscular dystrophies. Current projects include the promising SMT-M01 for DMD and SMT-B01 focused on metabolic disorders. The company has successfully raised over $10 million to support their innovative initiatives.
Management Team Overview:
- Micha Breakstone, PhD: CEO and Co-founder
- Jonathan Rosenfeld, PhD: CTO and Co-founder
- Carl Morris, PhD: Chief Scientific Officer
- Kristy Brown, PhD: SVP Translational Development
About OmniaBio
OmniaBio Inc. is a leading cell and gene therapy contract development and manufacturing organization (CDMO) specializing in innovative regenerative medicine solutions. They have significant expertise in manufacturing immune cell-based therapies and advanced gene therapy applications. With ongoing improvements in their clinical production capabilities, OmniaBio is well-positioned to meet the growing demand for advanced therapeutic solutions worldwide.
Frequently Asked Questions
What is the purpose of Somite Therapeutics and OmniaBio's collaboration?
The collaboration aims to advance the development of SMT-M01, a cell replacement therapy targeting Duchenne muscular dystrophy.
How does AI play a role in this partnership?
Somite utilizes AI technology to enhance the discovery and optimization processes for cell therapy manufacturing, improving efficiency and effectiveness.
What is Duchenne muscular dystrophy?
DMD is a severe genetic disorder characterized by progressive muscle degeneration and weakness, with no known cure available.
When do the companies expect to start clinical trials?
The initial phase one/two clinical trials for SMT-M01 are anticipated to begin within 18 to 24 months.
What other programs does Somite Therapeutics focus on?
Besides SMT-M01 for DMD, Somite Therapeutics is also developing SMT-B01 aimed at metabolic disorders.
